» Articles » PMID: 21990358

Reversible Major Histocompatibility Complex I-peptide Multimers Containing Ni(2+)-nitrilotriacetic Acid Peptides and Histidine Tags Improve Analysis and Sorting of CD8(+) T Cells

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2011 Oct 13
PMID 21990358
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

MHC-peptide multimers containing biotinylated MHC-peptide complexes bound to phycoerythrin (PE) streptavidin (SA) are widely used for analyzing and sorting antigen-specific T cells. Here we describe alternative T cell-staining reagents that are superior to conventional reagents. They are built on reversible chelate complexes of Ni(2+)-nitrilotriacetic acid (NTA) with oligohistidines. We synthesized biotinylated linear mono-, di-, and tetra-NTA compounds using conventional solid phase peptide chemistry and studied their interaction with HLA-A*0201-peptide complexes containing a His(6), His(12), or 2×His(6) tag by surface plasmon resonance on SA-coated sensor chips and equilibrium dialysis. The binding avidity increased in the order His(6) < His(12) < 2×His(6) and NTA(1) < NTA(2) < NTA(4), respectively, depending on the configuration of the NTA moieties and increased to picomolar K(D) for the combination of a 2×His(6) tag and a 2×Ni(2+)-NTA(2). We demonstrate that HLA-A2-2×His(6)-peptide multimers containing either Ni(2+)-NTA(4)-biotin and PE-SA- or PE-NTA(4)-stained influenza and Melan A-specific CD8+ T cells equal or better than conventional multimers. Although these complexes were highly stable, they very rapidly dissociated in the presence of imidazole, which allowed sorting of bona fide antigen-specific CD8+ T cells without inducing T cell death as well as assessment of HLA-A2-peptide monomer dissociation kinetics on CD8+ T cells.

Citing Articles

Overall avidity declines in TCR repertoires during latent CMV but not EBV infection.

Couturaud B, Doix B, Carretero-Iglesia L, Allard M, Pradervand S, Hebeisen M Front Immunol. 2023; 14:1293090.

PMID: 38053994 PMC: 10694213. DOI: 10.3389/fimmu.2023.1293090.


Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors.

Schmidt J, Chiffelle J, Perez M, Magnin M, Bobisse S, Arnaud M Nat Commun. 2023; 14(1):3188.

PMID: 37280206 PMC: 10244384. DOI: 10.1038/s41467-023-38946-z.


Bystander T cells in cancer immunology and therapy.

Meier S, Satpathy A, Wells D Nat Cancer. 2022; 3(2):143-155.

PMID: 35228747 DOI: 10.1038/s43018-022-00335-8.


Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation.

Duraiswamy J, Turrini R, Minasyan A, Barras D, Crespo I, Grimm A Cancer Cell. 2021; 39(12):1623-1642.e20.

PMID: 34739845 PMC: 8861565. DOI: 10.1016/j.ccell.2021.10.008.


MHC multimer: A Molecular Toolbox for Immunologists.

Chang J Mol Cells. 2021; 44(5):328-334.

PMID: 33972472 PMC: 8175149. DOI: 10.14348/molcells.2021.0052.


References
1.
Guillaume P, Dojcinovic D, Luescher I . Soluble MHC-peptide complexes: tools for the monitoring of T cell responses in clinical trials and basic research. Cancer Immun. 2009; 9:7. PMC: 2935769. View

2.
Xu X, Purbhoo M, Chen N, Mongkolsapaya J, Cox J, Meier U . A novel approach to antigen-specific deletion of CTL with minimal cellular activation using alpha3 domain mutants of MHC class I/peptide complex. Immunity. 2001; 14(5):591-602. DOI: 10.1016/s1074-7613(01)00133-9. View

3.
Cebecauer M, Guillaume P, Hozak P, Mark S, Everett H, Schneider P . Soluble MHC-peptide complexes induce rapid death of CD8+ CTL. J Immunol. 2005; 174(11):6809-19. DOI: 10.4049/jimmunol.174.11.6809. View

4.
Khan F, He M, Taussig M . Double-hexahistidine tag with high-affinity binding for protein immobilization, purification, and detection on ni-nitrilotriacetic acid surfaces. Anal Chem. 2006; 78(9):3072-9. DOI: 10.1021/ac060184l. View

5.
Steinhauer C, Wingren C, Khan F, He M, Taussig M, Borrebaeck C . Improved affinity coupling for antibody microarrays: engineering of double-(His)6-tagged single framework recombinant antibody fragments. Proteomics. 2006; 6(15):4227-34. DOI: 10.1002/pmic.200600036. View